Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Puma Biotechnology (PBYI)

Puma Biotechnology (PBYI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 125,025
  • Shares Outstanding, K 44,973
  • Annual Sales, $ 253,160 K
  • Annual Income, $ -29,130 K
  • 60-Month Beta 0.67
  • Price/Sales 0.47
  • Price/Cash Flow N/A
  • Price/Book 16.74
Trade PBYI with:

Options Overview Details

View History
  • Implied Volatility 163.15% ( -12.32%)
  • Historical Volatility 94.33%
  • IV Percentile 92%
  • IV Rank 23.03%
  • IV High 534.13% on 05/25/22
  • IV Low 52.13% on 09/09/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 107
  • Volume Avg (30-Day) 155
  • Put/Call OI Ratio 0.29
  • Today's Open Interest 3,179
  • Open Int (30-Day) 4,141

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate 0.02
  • Number of Estimates 1
  • High Estimate 0.02
  • Low Estimate 0.02
  • Prior Year -0.13
  • Growth Rate Est. (year over year) +115.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.46 +16.04%
on 06/13/22
3.13 -8.95%
on 06/24/22
+0.17 (+6.34%)
since 06/07/22
3-Month
1.60 +78.12%
on 05/12/22
3.17 -10.09%
on 04/08/22
-0.27 (-8.65%)
since 04/07/22
52-Week
1.60 +78.12%
on 05/12/22
8.78 -67.54%
on 07/12/21
-5.41 (-65.50%)
since 07/07/21

Most Recent Stories

More News
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on July 1, 2022, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted...

PBYI : 2.83 (+1.80%)
Celldex (CLDX) Surges 9%: Is This an Indication of Further Gains?

Celldex (CLDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

CLDX : 26.59 (+10.84%)
PBYI : 2.83 (+1.80%)
Why Is Reata Pharmaceuticals, Inc. (RETA) Up 53.1% Since Last Earnings Report?

Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

RETA : 36.95 (+1.26%)
PBYI : 2.83 (+1.80%)
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on June 3, 2022, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted...

PBYI : 2.83 (+1.80%)
Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, presented results from the Phase II SUMMIT trial, assessing the efficacy of combined neratinib, fulvestrant, and trastuzumab in patients...

PBYI : 2.83 (+1.80%)
Puma Biotechnology Presents Final Results from the Biliary Tract Cohort of the Phase 2 SUMMIT ‘Basket’ Trial of Neratinib at the ASCO 2022 Annual Meeting

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, presented final results from the Phase II SUMMIT ‘basket’ trial, assessing the efficacy of neratinib in treatment-refractory patients...

PBYI : 2.83 (+1.80%)
Puma Biotechnology Announces Publication of Abstracts on Neratinib for the 2022 ASCO Annual Meeting

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the publication of two abstracts on neratinib to be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual...

PBYI : 2.83 (+1.80%)
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on May 9, 2022, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted...

PBYI : 2.83 (+1.80%)
Puma Biotech (PBYI) Q1 Earnings Beat, Nerlynx Sales Fall Y/Y

Puma Biotech (PBYI) Q1 loss narrows while sales come in line with estimates. PBYI's stock declines in the after-market trading session following the news.

RHHBY : 41.7700 (-0.12%)
ALKS : 31.65 (-0.69%)
PBYI : 2.83 (+1.80%)
DCPH : 13.74 (-1.29%)
Puma Biotech (PBYI) Reports Q1 Loss, Misses Revenue Estimates

Puma Biotech (PBYI) delivered earnings and revenue surprises of 38.46% and 0.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

PBYI : 2.83 (+1.80%)
XENE : 33.43 (+0.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Puma Biotechnology, Inc. is a small cancer biotech whose only marketed product, Nerlynx (neratinib) was launched in the United Statesfor the treatment of early stage HER2-positive breast cancer in patients who have been previously treated with Roche's Herceptin-based adjuvant therapy. The drug was also...

See More

Key Turning Points

3rd Resistance Point 3.02
2nd Resistance Point 2.91
1st Resistance Point 2.84
Last Price 2.83
1st Support Level 2.67
2nd Support Level 2.56
3rd Support Level 2.49

See More

52-Week High 8.78
Fibonacci 61.8% 6.04
Fibonacci 50% 5.19
Fibonacci 38.2% 4.34
Last Price 2.83
52-Week Low 1.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar